DNA supercoil

Cytovance Biologics announces Plasmid DNA Manufacturing: An Optimized Platform Process Webinar

Retrieved on: 
Monday, June 14, 2021
Life sciences, Branches of biology, Biology, Molecular biology, Pharmaceutical industry, Gene delivery, Biotechnology, DNA, Plasmid, Biopharmaceutical, Contract manufacturing organization, DNA supercoil

OKLAHOMA CITY, June 14, 2021 (GLOBE NEWSWIRE) -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process.

Key Points: 
  • OKLAHOMA CITY, June 14, 2021 (GLOBE NEWSWIRE) -- Cytovance Biologics, a leading biopharmaceutical contract development and manufacturing organization (CDMO) of mammalian, microbial and gene therapy biologics, announces the next webinar of its 2021 series: pDNA Manufacturing: An Optimized Platform Process.
  • Our featured speakers will discuss strain selection, plasmid optimization, media composition and fermentation conditions necessary to produce high quality supercoiled plasmid DNA.
  • The demand for large quantities of high-quality supercoiled plasmid DNA (Sc-pDNA) has increased over the years due to its primary role in gene therapy.
  • The platform purification process developed by Cytovance addresses the main challenges in large scale manufacturing of pDNA such as scalability, quantity and quality.

Twist Bioscience Synthetic DNA Stores New Netflix Original Series ‘BIOHACKERS’

Retrieved on: 
Thursday, August 20, 2020
Technology, Entertainment, Genetics, Nanotechnology, Mobile Entertainment, Biotechnology, General Entertainment, TV and Radio, Health, Helices, Branches of biology, DNA, Biology, Articles, Molecular biology, Twist Bioscience, Nucleic acids, Biohackers, DNA supercoil, Synthetic Genomics, Hair twists, BIOHACKERS, Twist Bioscience Corporation

Twist Bioscience Corporation (Nasdaq: TWST) today announced that for the first time, an episode of a Netflix Original Series has been stored in Twists synthetic DNA.

Key Points: 
  • Twist Bioscience Corporation (Nasdaq: TWST) today announced that for the first time, an episode of a Netflix Original Series has been stored in Twists synthetic DNA.
  • Its exciting to ground the fictional series, which expounds beyond the boundaries of what is possible with DNA today, with the reality of preserving groundbreaking cultural media in synthetic DNA.
  • Released today exclusively on Netflix (NASDAQ: NFLX) and starring Luna Wedler and Jessica Schwarz, BIOHACKERS is a gripping science thriller.
  • This code is then built, base by base into strands of synthetic DNA by Twist Bioscience to store the series for thousands of years.

Twist Bioscience Launches New NGS Solutions, Highlights Customers at 2020 Advances in Genome Biology and Technology Conference

Retrieved on: 
Monday, February 24, 2020
Software, Research, Pharmaceutical, Oncology, Data management, Technology, Semiconductor, Genetics, Science, Nanotechnology, Biotechnology, Health, Branches of biology, Biotechnology, Life sciences, Helices, Molecular biology, DNA, Systems biology, Synthetic biology, DNA supercoil, Biology, the Twist NGS Target Enrichment Solutions, Twist Bioscience Corporation

Twist is highlighting these new solutions as well as customer testimonials at the 2020 Advances in Genome Biology and Technology (AGBT) meeting, held from February 23, 2020 to February 26, 2020, in Florida.

Key Points: 
  • Twist is highlighting these new solutions as well as customer testimonials at the 2020 Advances in Genome Biology and Technology (AGBT) meeting, held from February 23, 2020 to February 26, 2020, in Florida.
  • During the meeting, several customers will demonstrate their use of Twists NGS target enrichment solutions for numerous clinical research applications.
  • Building on these important use cases, we are committed to continue to deliver DNA-based products that interrogate biology and enable improved clinical outcomes.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Twist Bioscience Announces Completion of $50 Million Registered Direct Offering Priced At-The-Market

Retrieved on: 
Friday, January 31, 2020
Health, Technology, Nanotechnology, Genetics, Research, Science, Biotechnology, Life sciences, Articles, Biology, Biotechnology, Helices, U.S. Securities and Exchange Commission, Molecular genetics, Registration statement, Synthetic biology, Twist Bioscience, Prospectus, DNA supercoil, Health, Technology, Nanotechnology, Genetics, Research, Science, Biotechnology, Life sciences, Articles, Biology, Biotechnology, Helices, U.S. Securities and Exchange Commission, Molecular genetics, Registration statement, Synthetic biology, Twist Bioscience, Prospectus, DNA supercoil

The prospectus supplement relates to Twists registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on December 13, 2019.

Key Points: 
  • The prospectus supplement relates to Twists registration statement on Form S-3, which was declared effective by the Securities and Exchange Commission on December 13, 2019.
  • Twist intends to use the proceeds from the at-the-market offering for working capital purposes and to fund its growth.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.

Twist Bioscience Promotes Patrick Weiss to Chief Operating Officer Setting Stage for Future Growth

Retrieved on: 
Monday, January 13, 2020
Research, Technology, Genetics, Nanotechnology, Software, Biotechnology, Health, Data management, Science, Other Science, Branches of biology, Articles, Biology, Twist Bioscience, DNA, Molecular biology, Biotechnology, Emerging technologies, Molecular genetics, DNA supercoil, Synthetic biology

Patrick has built the operational infrastructure at Twist from the beginning, transforming a complex manufacturing process into a robust commercial platform, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.

Key Points: 
  • Patrick has built the operational infrastructure at Twist from the beginning, transforming a complex manufacturing process into a robust commercial platform, said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience.
  • Dr. Banyai is a co-founder and director of the company and together with Bill Peck, Ph.D., chief technology officer of Twist Bioscience, developed the silicon-based DNA synthesis platform, including both the software and hardware infrastructure.
  • He led the integration of Genome Compiler, a company Twist acquired in April 2016, and has been responsible for all facilities expansion.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.

Twist Bioscience to Present at the 38th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Monday, January 6, 2020
Health, Technology, Nanotechnology, Genetics, Research, Science, Biotechnology, Branches of biology, Articles, Biology, Twist Bioscience, Biotechnology, DNA, Molecular biology, Synthetic biology, DNA supercoil

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. Pacific Time in San Francisco.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder of Twist Bioscience, will present at the 38th Annual J.P. Morgan Healthcare Conference on Wednesday, January 15th at 8:30 a.m. Pacific Time in San Francisco.
  • A replay of the presentation will be archived for a period of 30 days following the conclusion of the live event.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience to Present at Two Investor Conferences in September

Retrieved on: 
Friday, August 30, 2019
Biotechnology, Technology, Health, Medical devices, Research, Nanotechnology, Genetics, Science, Life sciences, Articles, Biology, Biotechnology, Twist Bioscience, DNA, Molecular biology, Synthetic biology, DNA supercoil, DNA synthesis, Biopharmaceutical

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Jim Thorburn, CFO of Twist Bioscience, will present at two investor conferences in September:

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience and Jim Thorburn, CFO of Twist Bioscience, will present at two investor conferences in September:
    Baird 2019 Global Healthcare Conference on Thursday, September 5th at 9:05 a.m.
  • ET
    Each fireside chat will be webcast live and can be accessed by visiting the Presentations page of the investor relations section of the company's website here .
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.

Twist Bioscience to Present at the Jefferies 2019 Global Healthcare Conference

Retrieved on: 
Tuesday, May 28, 2019
Health, Biotechnology, Genetics, Research, Other Science, Science, Life sciences, Articles, Biology, Biotechnology, Twist Bioscience, Molecular genetics, DNA, Molecular biology, Synthetic biology, Biopharmaceutical, DNA synthesis, DNA supercoil

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4th at 8 a.m.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4th at 8 a.m.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.

Twist Bioscience Strengthens Board With Semiconductor and Storage Expert Nelson C. Chan

Retrieved on: 
Thursday, May 23, 2019
Technology, Data management, Semiconductor, Health, Biotechnology, Genetics, SanDisk, DNA, Molecular biology, DNA supercoil, Industries, American culture, California

Mr. Chan has been an advisor to Twist for the last 18 months, providing guidance on its DNA data storage vertical.

Key Points: 
  • Mr. Chan has been an advisor to Twist for the last 18 months, providing guidance on its DNA data storage vertical.
  • At SanDisk, Mr. Chan helped drive the business from startup to over $3 billion in annual revenues.
  • I look forward to sharing my expertise as Twist moves toward the commercialization of a new data storage media in DNA, commented Mr. Chan.
  • Mr. Chan replaces Paul Conley, Ph.D., managing director of Paladin Capital Group, who has served on Twists board of directors since 2013.

Twist Bioscience to Present at the UBS Global Healthcare Conference

Retrieved on: 
Thursday, May 16, 2019
Technology, Data management, Nanotechnology, Health, Biotechnology, Genetics, Life sciences, Articles, Biology, Biotechnology, Twist Bioscience, Molecular biology, Molecular genetics, DNA, Synthetic biology, Biopharmaceutical, DNA synthesis, DNA supercoil

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20th at 11:30 a.m.

Key Points: 
  • Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, today announced that Emily Leproust, Ph.D., CEO and co-founder, will present at the UBS Global Healthcare Conference on Monday, May 20th at 11:30 a.m.
  • Twist Bioscience is a leading and rapidly growing synthetic biology company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology.
  • Twist is also pursuing longer-term opportunities in digital data storage in DNA and biologics drug discovery.
  • Twist makes products for use across many industries including healthcare, industrial chemicals, agriculture and academic research.